Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities☆

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities☆

Patients with high risk myelodysplasia (HR-MDS) and acute myeloid leukaemia (AML) with chromosomal changes involving deletion of the long arm of chromosome 5 (del5q), especially with complex karyotype, rarely have a durable response to combination chemotherapy. In the subgroup with monosomal karyoty...

Full description

Bibliographic Details
Main Authors: Dennis, M., Culligan, D., Karamitros, D., Vyas, P., Johnson, P., Russell, N.H., Cavenagh, J., Szubert, A., Hartley, S., Brown, J., Bowen, D.
Format: Online
Language:English
Published: Elsevier 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850387/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850387/

Similar Items